GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Earnings per Share (Diluted)

Antares Pharma (Antares Pharma) Earnings per Share (Diluted) : $0.24 (TTM As of Mar. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Earnings per Share (Diluted)?

Antares Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2022 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $0.24.

Antares Pharma's EPS (Basic) for the three months ended in Mar. 2022 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 was $0.24.

Antares Pharma's EPS without NRI for the three months ended in Mar. 2022 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $0.24.

During the past 12 months, Antares Pharma's average EPS without NRIGrowth Rate was -33.30% per year.

During the past 13 years, Antares Pharma's highest 3-Year average EPS without NRI Growth Rate was 60.30% per year. The lowest was -75.40% per year. And the median was 17.95% per year.


Antares Pharma Earnings per Share (Diluted) Historical Data

The historical data trend for Antares Pharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Earnings per Share (Diluted) Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.04 -0.01 0.33 0.26

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.03 0.19 -0.01

Competitive Comparison of Antares Pharma's Earnings per Share (Diluted)

For the Medical Instruments & Supplies subindustry, Antares Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Antares Pharma's PE Ratio falls into.



Antares Pharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Antares Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2021 is calculated as

Diluted Earnings Per Share (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(46.289-0)/174.733
=0.26

Antares Pharma's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2022 is calculated as

Diluted Earnings Per Share (Q: Mar. 2022 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-2.321-0)/170.104
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Antares Pharma  (NAS:ATRS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Antares Pharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447

Antares Pharma (Antares Pharma) Headlines

From GuruFocus